Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-NMDA receptor encepha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-nmda Receptor Encephalitis
• Lgi1 Autoimmune Encephalitis

Drugs mentioned

• Satralizumab (Enspryng) (satralizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis | Phase 3 | Status: RECRUITING